|
Burkitt Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Oligonucleotide sets that probe breakpoints of <i>IGH-BCL2</i> (immunoglobulin heavy-apoptosis regulator) in follicular lymphoma (FL), <i>MYC-IGH</i> (MYC proto-oncogene, bHLH transcription factor-immunoglobulin heavy) in Burkitt lymphoma (BL) and <i>BCR-ABL1</i> (RhoGEF and GTPase activating protein-ABL proto-oncogene 1, non-receptor tyrosine kinase) in chronic myelogenous leukemia (CML) were designed.
|
28515100 |
2017 |
|
Burkitt Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A high Ki-67 proliferation index and positive bcl-2 staining (on cytospin slides or cell block material) of cases not conforming to typical Burkitt lymphoma morphology should prompt FISH analysis for c-MYC and/or IGH-BCL2 rearrangements to identify DHL, particularly if tissue biopsy is not expected.
|
21560252 |
2011 |
|
Burkitt Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Patients demonstrating a terminal deoxynucleotidyl transferase (TdT)-positive precursor B cell phenotype with IGH-MYC rearrangement have been reported to be molecularly distinct from BL and closer to B-ALL/LBL.
|
31705772 |
2020 |
|
Burkitt Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
|
20118770 |
2010 |
|
Burkitt Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The chromosomal translocation t(8;14)(q24;q32) with juxtaposition of MYC to enhancer elements in the immunoglobulin heavy chain (IGH) gene locus is the genetic hallmark of the majority of Burkitt lymphoma and a subset of Diffuse large B-cell lymphoma patients.
|
23673335 |
2013 |
|
Burkitt Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We performed a polymerase chain reaction analysis of three regions of the VDJ junction of the immunoglobulin heavy chain (IGH) gene and compared the clonality of the first and second BL lesions, which were found to be clonally distinct.
|
25555480 |
2015 |
|
Burkitt Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The DNA sequence of the third-complementarity-determining region (CDRIII) of the immunoglobulin heavy chain (IgH) gene in a case of Burkitt's lymphoma was determined by polymerase chain reaction (PCR) using template DNA extracted from a smear stored at room temperature for more than one year.
|
1908851 |
1991 |
|
Burkitt Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The chromosomal translocation t(8;14) is the hallmark of Burkitt's-lymphoma (BL) and fuses the proto-oncogene c-MYC to the IGH locus.
|
17541401 |
2007 |
|
Burkitt Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Thus, the capacity of Tat to spontaneously penetrate B-cells could be sufficient to favor the occurrence of MYC-IGH oncogenic rearrangements during erroneous repair, a plausible cause for the increased incidence of Burkitt lymphoma in the HIV-infected population.
|
30701532 |
2019 |
|
Burkitt Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
IGH switch breakpoints in Burkitt lymphoma: exclusive involvement of noncanonical class switch recombination.
|
16736499 |
2006 |
|
Burkitt Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Cryptic insertion of <i>MYC</i> exons 2 and 3 into the IGH locus detected by whole genome sequencing in a case of MYC-negative Burkitt lymphoma.
|
31073073 |
2019 |
|
Burkitt Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We have molecularly characterized the recently established Burkitt lymphoma cell line BLUE-1 that carries a t(6;20)(q15;q11.2) rearrangement in addition to the typical t(8;14) with MYC-IGH fusion.
|
21412927 |
2011 |
|
Lymphoma, Follicular
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Molecular diagnostic laboratories face such difficulties with the BCL2-IGH translocation in follicular lymphoma and with internal tandem duplication mutation of the FLT3 gene in leukemia, where breakpoints are widely distributed, mutations may be multiple, signal strength is low, and background noise is elevated.
|
21227398 |
2011 |
|
Lymphoma, Follicular
|
0.400 |
Biomarker
|
disease |
BEFREE |
Oligonucleotide sets that probe breakpoints of <i>IGH-BCL2</i> (immunoglobulin heavy-apoptosis regulator) in follicular lymphoma (FL), <i>MYC-IGH</i> (MYC proto-oncogene, bHLH transcription factor-immunoglobulin heavy) in Burkitt lymphoma (BL) and <i>BCR-ABL1</i> (RhoGEF and GTPase activating protein-ABL proto-oncogene 1, non-receptor tyrosine kinase) in chronic myelogenous leukemia (CML) were designed.
|
28515100 |
2017 |
|
Lymphoma, Follicular
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The t(14;18)(q32;q21) involving the IGH and the MALT1 gene has previously been described in PCMZL, whereas the t(14;18)(q32;q21) IGH/BCL2 seems to be restricted to follicular lymphoma and diffuse large B-cell lymphoma.
|
17519619 |
2007 |
|
Lymphoma, Follicular
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Intraclonal heterogeneity in follicular lymphoma (FL) is apparent from studies of somatic hypermutation (SHM) caused by activation-induced deaminase (AID) in IGH.
|
25311808 |
2014 |
|
Lymphoma, Follicular
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Comparative analysis between RQ-PCR and digital droplet PCR of BCL2/IGH gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma.
|
28419517 |
2017 |
|
Lymphoma, Follicular
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Since 2000, we have investigated 67 consecutive patients with stage I/II follicular lymphoma (FL) for the presence of BCL2/IGH rearrangements by polymerase chain reaction (PCR), real time quantitative PCR (RQ-PCR) and digital droplet PCR (ddPCR).
|
31385309 |
2020 |
|
Lymphoma, Follicular
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Although the majority of patients with follicular lymphoma (FL) harbor the t(14;18)(q32;q21) IGH/BCL2 gene rearrangement that leads to the overexpression of BCL2 protein, approximately 20% of FL cases lack t(14;18)(q32;q21).
|
31789408 |
2020 |
|
Lymphoma, Follicular
|
0.400 |
Biomarker
|
disease |
BEFREE |
We performed interphase fluorescence in situ hybridization (FISH) analysis to detect Bcl-2/IgH, Bcl-6 gene rearrangement, Bcl-2 gene amplification, and the cyclinD1/IgH gene in formalin-fixed paraffin embedded specimens from our FL archives.
|
15723651 |
2005 |
|
Lymphoma, Follicular
|
0.400 |
Biomarker
|
disease |
BEFREE |
The sequence analysis of the IgH gene revealed both of cells originated from the same clone, showing that the aggressive BL-like tumor originated from the FL-like clones simultaneously found in the bone marrow.
|
21184290 |
2011 |
|
Lymphoma, Follicular
|
0.400 |
Biomarker
|
disease |
BEFREE |
B-cell clonality was detected by combined use of the IGH and IGK multiplex PCR assays in all 260 definitive cases of B-cell chronic lymphocytic leukemia (n=56), mantle cell lymphoma (n=54), marginal zone lymphoma (n=41) and follicular lymphoma (n=109).
|
17170731 |
2007 |
|
Lymphoma, Follicular
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The most common genetic aberration in follicular lymphoma (FL) is the t(14;18)(q32;q21) translocation that juxtaposes the antiapoptotic BCL2 gene with the promoter of the immunoglobulin heavy chain (IgH) gene.
|
17964648 |
2008 |
|
Lymphoma, Follicular
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the first case, the FL was negative for IGH-BCL2 and harbored a novel IGH-associated translocation; in the second case, the CL manifested in the skin.
|
22431543 |
2012 |
|
Lymphoma, Follicular
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The translocation t(14;18) between the BCL-2 oncogene and the Ig heavy chain (IgH) gene provides the molecular basis for the development of follicular lymphomas.
|
8461469 |
1993 |